News

Filter

Current filters:

Eli Lilly

1 to 9 of 356 results

FDA safety review of Zyprexa Relprevv calls for no changes to current prescribing

24-03-2015

The US Food and Drug Administration has concluded a review of a study undertaken to determine the cause…

Eli LillyHealthcareNeurologicalPharmaceuticalRegulationUSAZyprexa Relprevv

Pfizer and Lilly gear up to resume Phase III chronic pain program for tanezumab

23-03-2015

US pharma majors Pfizer and Eli Lilly both saw their shares rise in pre-market trading today, as they…

Eli LillyLicensingNeurologicalPfizerPharmaceuticalRegulationUSA

Lilly and Innovent collaborate to bring potential cancer drugs to market

20-03-2015

US pharma major Eli Lilly has joined forces with Innovent Biologics, a leading Chinese biotech firm,…

ChinaEli LillyGlobalInnovent BiologicsLicensingOncologyPharmaceuticalResearch

Eli Lilly collaborates with Hanmi on BTK inhibitor

19-03-2015

US pharma major Eli Lilly and South Korean drugmaker Hanmi Pharmaceutical have entered into an exclusive…

Anti-Arthritics/RheumaticsEli LillyHanmi PharmaceuticalImmunologicalsLicensingPharmaceutical

Lilly, GSK and Janssen join UK government's $100 million Dementia Discovery Fund

Lilly, GSK and Janssen join UK government's $100 million Dementia Discovery Fund

17-03-2015

The UK’s Health Secretary Jeremy Hunt has announced a collaborative dementia research initiative between…

Eli LillyGSKJanssenNeurologicalPharmaceuticalResearchUK

Now German court rules against Lilly in Alimta vitamin regimen patent case

Now German court rules against Lilly in Alimta vitamin regimen patent case

07-03-2015

The German Court of Appeal has ruled that US pharma major Eli Lilly’s vitamin regimen patent for its…

ActavisAlimtaEli LillyGermanyLegalOncologyPatentsPharmaceutical

US FDA warns on over-prescribing of testosterone products

US FDA warns on over-prescribing of testosterone products

04-03-2015

The US Food and Drug Administration is requiring that the manufacturers of all approved prescription…

AbbVieAndroGelAxironEli LillyMen's HealthPharmaceuticalRegulationUSA

Lilly licenses pomaglumetad methionil to Denovo as potential schizophrenia therapy

Lilly licenses pomaglumetad methionil to Denovo as potential schizophrenia therapy

03-03-2015

US drug major Eli Lilly has licensed late-stage neuroscience drug pomaglumetad methionil (mGlu2/3 receptor…

Eli LillyLicensingNeurologicalPharmaceuticalpomaglumetad methionilUSA

1 to 9 of 356 results

Back to top